应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ROIV Roivant Sciences Ltd.
盘后交易 01-20 16:52:12 EST
22.98
-0.15
-0.65%
盘后
22.98
+0.00
0.00%
16:10 EST
最高
22.99
最低
22.41
成交量
419.06万
今开
22.73
昨收
23.13
日振幅
2.51%
总市值
159.82亿
流通市值
95.27亿
总股本
6.95亿
成交额
9,538万
换手率
1.01%
流通股本
4.15亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Jefferies:Roivant(ROIV.US)2026年迎三大催化剂,目标价看高至 24 美元
智通财经 · 2025-12-31
Jefferies:Roivant(ROIV.US)2026年迎三大催化剂,目标价看高至 24 美元
Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日
美股速递 · 2025-12-11
Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日
Roivant Sciences:Lnp诉讼持续推进,法院于2025年9月在Pfizer/BioNTech案件中作出有利的Markman裁决
美股速递 · 2025-11-10
Roivant Sciences:Lnp诉讼持续推进,法院于2025年9月在Pfizer/BioNTech案件中作出有利的Markman裁决
Roivant将在11月10日(星期一)发布2025年9月30日结束的第二季度财务业绩及业务更新
美股速递 · 2025-10-28
Roivant将在11月10日(星期一)发布2025年9月30日结束的第二季度财务业绩及业务更新
美股异动|生物制药公司Roivant涨超13%,Brepocitinib三期试验数据表现积极
老虎资讯综合 · 2025-09-17
美股异动|生物制药公司Roivant涨超13%,Brepocitinib三期试验数据表现积极
Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果
美股速递 · 2025-09-17
Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果
Roivant Sciences Ltd.盘中异动 临近收盘急速拉升5.01%
市场透视 · 2025-09-12
Roivant Sciences Ltd.盘中异动 临近收盘急速拉升5.01%
Pulmovant旗下药物Mosliciguat获得日本孤儿药认定,用于治疗间质性肺病相关肺动脉高压
美股速递 · 2025-09-04
Pulmovant旗下药物Mosliciguat获得日本孤儿药认定,用于治疗间质性肺病相关肺动脉高压
Roivant Sciences Ltd.公布持久性数据及六个月无治疗缓解期结果,或将改变难治性Graves病治疗模式
美股速递 · 2025-09-04
Roivant Sciences Ltd.公布持久性数据及六个月无治疗缓解期结果,或将改变难治性Graves病治疗模式
Roivant Sciences Ltd.盘中异动 下午盘股价大跌5.03%
市场透视 · 2025-03-04
Roivant Sciences Ltd.盘中异动 下午盘股价大跌5.03%
异动解读 | 生物技术股Roivant Sciences Ltd.(ROIV)盘中大涨5.51% 市场看好公司前景
异动解读 · 2025-02-10
异动解读 | 生物技术股Roivant Sciences Ltd.(ROIV)盘中大涨5.51% 市场看好公司前景
Roivant Sciences Ltd.盘中异动 早盘股价大涨5.10%
市场透视 · 2025-02-10
Roivant Sciences Ltd.盘中异动 早盘股价大涨5.10%
Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28),销售额900.2万美元未达预期1599.9万美元
财报速递 · 2025-02-10
Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28),销售额900.2万美元未达预期1599.9万美元
特朗普2.0时代即将开启,投资机会如何掘金?
招商基金 · 2025-01-20
特朗普2.0时代即将开启,投资机会如何掘金?
Roivant Sciences Ltd.盘中异动 下午盘快速上涨5.03%
市场透视 · 2024-11-23
Roivant Sciences Ltd.盘中异动 下午盘快速上涨5.03%
加载更多
公司概况
公司名称:
Roivant Sciences Ltd.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Roivant Sciences Ltd.是一家于2020年7月6日成立的注册于百慕大群岛的公司。Roivant的使命是通过将每一个低效率都视为机会来改善为患者提供的医疗保健服务。Roivant通过以创造性的方式构建技术和培养人才,利用Roivant平台推出“Vants”——灵活且专注的生物制药和健康技术公司,从而更快地开发变革性药物。
发行价格:
--
{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":22.98,"timestamp":1768942800000,"preClose":23.13,"halted":0,"volume":4190646,"hourTrading":{"tag":"盘后","latestPrice":22.98,"preClose":22.98,"latestTime":"16:10 EST","volume":84407,"amount":1939664.250486,"timestamp":1768943404725,"change":0,"changeRate":0,"amplitude":0.019365},"delay":0,"changeRate":-0.006485084306095918,"floatShares":414556768,"shares":695491615,"eps":-0.535859,"marketStatus":"盘后交易","change":-0.15,"latestTime":"01-20 16:52:12 EST","open":22.73,"high":22.99,"low":22.4101,"amount":95376865.155036,"amplitude":0.025071,"askPrice":23.78,"askSize":389,"bidPrice":22.54,"bidSize":88,"shortable":3,"etf":0,"ttmEps":-0.535859,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1768957200000},"marketStatusCode":4,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":23.13,"preHourTrading":{"tag":"盘前","latestPrice":22.11,"preClose":23.13,"latestTime":"09:25 EST","volume":1670,"amount":37420.86735,"timestamp":1768919112701,"change":-1.02,"changeRate":-0.044099,"amplitude":0.028102},"postHourTrading":{"tag":"盘后","latestPrice":22.98,"preClose":22.98,"latestTime":"16:10 EST","volume":84407,"amount":1939664.250486,"timestamp":1768943404725,"change":0,"changeRate":0,"amplitude":0.019365},"volumeRatio":0.565501,"impliedVol":0.4226,"impliedVolPercentile":0.7769},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"2595726511","title":"Jefferies:Roivant(ROIV.US)2026年迎三大催化剂,目标价看高至 24 美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595726511","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595726511?lang=zh_cn&edition=full","pubTime":"2025-12-31 14:41","pubTimestamp":1767163270,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,Jefferies发布深度研报,聚焦生物技术公司Roivant Sciences的投资前景,通过严谨的财务模型与行业分析,揭示了其未来三大核心催化剂及估值逻辑。研报指出,2026年将成为公司关键转折点,三大催化剂或推动股价显著上行。第三项催化剂为Priovant的brepo药物三期NIU试验数据,其时间节点提前至2026年下半年。基于此,Jefferies给予Roivant“买入”评级,目标价24美元,较最新收盘价21.63美元有10.95%上行空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Jefferies:Roivant(ROIV.US)2026年迎三大催化剂,目标价看高至 24 美元","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ROIV"],"gpt_icon":0},{"id":"1104547270","title":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","url":"https://stock-news.laohu8.com/highlight/detail?id=1104547270","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104547270?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:39","pubTimestamp":1765456740,"startTime":"0","endTime":"0","summary":"Roivant强调持续的管线进展及公司下一阶段增长的展望——2025投资者日","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"1185595231","title":"Roivant Sciences:Lnp诉讼持续推进,法院于2025年9月在Pfizer/BioNTech案件中作出有利的Markman裁决","url":"https://stock-news.laohu8.com/highlight/detail?id=1185595231","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185595231?lang=zh_cn&edition=full","pubTime":"2025-11-10 20:16","pubTimestamp":1762777002,"startTime":"0","endTime":"0","summary":"Roivant Sciences:Lnp诉讼持续推进,法院于2025年9月在Pfizer/BioNTech案件中作出有利的Markman裁决","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"1142073891","title":"Roivant将在11月10日(星期一)发布2025年9月30日结束的第二季度财务业绩及业务更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1142073891","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142073891?lang=zh_cn&edition=full","pubTime":"2025-10-28 04:11","pubTimestamp":1761595872,"startTime":"0","endTime":"0","summary":"Roivant将在11月10日(星期一)发布2025年9月30日结束的第二季度财务业绩及业务更新。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1123131695","title":"美股异动|生物制药公司Roivant涨超13%,Brepocitinib三期试验数据表现积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1123131695","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123131695?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:15","pubTimestamp":1758118526,"startTime":"0","endTime":"0","summary":"9月17日,生物制药公司$Roivant Sciences(ROIV)$涨超13%,宣布Brepocitinib药物三期研究数据积极。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"bf1f9917e89d16c929d49ce909869251","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"1110459212","title":"Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1110459212","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110459212?lang=zh_cn&edition=full","pubTime":"2025-09-17 19:02","pubTimestamp":1758106922,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.和Priovant宣布Brepocitinib治疗皮肌炎的3期Valor研究在52周安慰剂对照试验中获得积极结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2566591155","title":"Roivant Sciences Ltd.盘中异动 临近收盘急速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566591155","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566591155?lang=zh_cn&edition=full","pubTime":"2025-09-12 03:36","pubTimestamp":1757619374,"startTime":"0","endTime":"0","summary":"北京时间2025年09月12日03时36分,Roivant Sciences Ltd.股票出现异动,股价快速拉升5.01%。截至发稿,该股报14.46美元/股,成交量1017.08万股,换手率1.49%,振幅4.61%。Roivant Sciences Ltd.股票所在的生物技术行业中,整体涨幅为1.19%。Roivant Sciences Ltd.公司简介:Roivant Sciences Ltd是一家处于商业阶段的生物制药公司,致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250912033614a71c8b19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250912033614a71c8b19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1154255704","title":"Pulmovant旗下药物Mosliciguat获得日本孤儿药认定,用于治疗间质性肺病相关肺动脉高压","url":"https://stock-news.laohu8.com/highlight/detail?id=1154255704","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154255704?lang=zh_cn&edition=full","pubTime":"2025-09-04 19:00","pubTimestamp":1756983631,"startTime":"0","endTime":"0","summary":"Pulmovant宣布,其药物Mosliciguat已获得日本监管部门颁发的孤儿药认定,该药物用于治疗间质性肺病相关肺动脉高压(Ph-Ild)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1179535523","title":"Roivant Sciences Ltd.公布持久性数据及六个月无治疗缓解期结果,或将改变难治性Graves病治疗模式","url":"https://stock-news.laohu8.com/highlight/detail?id=1179535523","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179535523?lang=zh_cn&edition=full","pubTime":"2025-09-04 01:03","pubTimestamp":1756918998,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.近日发布了关于持久性治疗效果和六个月无治疗缓解期的临床数据,这些数据显示出改变未受控制Graves病患者治疗范式的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2516663104","title":"Roivant Sciences Ltd.盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663104?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:07","pubTimestamp":1741032469,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时07分,Roivant Sciences Ltd.股票出现波动,股价急速跳水5.03%。截至发稿,该股报10.20美元/股,成交量383.384万股,换手率0.54%,振幅5.77%。Roivant Sciences Ltd.股票所在的生物技术行业中,整体涨幅为0.17%。Roivant Sciences Ltd.公司简介:Roivant Sciences Ltd是一家处于商业阶段的生物制药公司,致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304040749a25d9d08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"1117070208","title":"异动解读 | 生物技术股Roivant Sciences Ltd.(ROIV)盘中大涨5.51% 市场看好公司前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1117070208","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117070208?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:52","pubTimestamp":1739199156,"startTime":"0","endTime":"0","summary":"生物技术公司Roivant Sciences Ltd.今日盘中股价大涨5.51%,引发市场关注。这或与以下几个原因有关:. 首先,公司最新财报数据获得市场认可。公司继续积极推进旗下重磅药物如VTAMA、Batoclimab等的研发。其次,券商机构对ROIV股票给予了较高评级。这表明分析师看好ROIV的长期增长前景。最后,生物技术整个行业今日整体呈现上涨趋势,带动了ROIV作为龙头股的表现。如Ocean Biomedical、Biodexa等个股涨幅较大,再次证明该行业的资金持续保持流入态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ROIV"],"gpt_icon":0},{"id":"2510865319","title":"Roivant Sciences Ltd.盘中异动 早盘股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510865319","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510865319?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:31","pubTimestamp":1739197919,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时31分,Roivant Sciences Ltd.股票出现波动,股价快速拉升5.10%。截至发稿,该股报11.45美元/股,成交量7.964万股,换手率0.01%,振幅1.26%。Roivant Sciences Ltd.股票所在的生物技术行业中,整体涨幅为0.38%。Roivant Sciences Ltd.公司简介:Roivant Sciences Ltd是一家处于商业阶段的生物制药公司,致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223159988077f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223159988077f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"1191608976","title":"Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28),销售额900.2万美元未达预期1599.9万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191608976","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191608976?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:17","pubTimestamp":1739189856,"startTime":"0","endTime":"0","summary":"Roivant Sciences 报告季度每股亏损$,优于分析师一致预期的$,相差28.57%。这一结果较去年同期的每股亏损$增长了4.76%。公司报告季度销售额为900.2万美元,未达到分析师一致预期的1599.9万美元,相差43.60%。这较去年同期的销售额1556万美元下降了42.05%。以上内容来自Benzinga Earnings专栏,原文如下:Roivant Sciences reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 28.57 percent. This is a 4.76 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $9.02 million which missed the analyst consensus estimate of $15","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28),销售额900.2万美元未达预期1599.9万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启,投资机会如何掘金?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启,有哪些投资机会可以布局?值得一提的是,科技股在特朗普任期内表现尤为突出,成为推动美股上涨的主要力量。在特朗普第一个任期内,美元整体表现相对弱势。4年任期内,美元指数累计下跌了10.53%。而纵观全球市场,在特朗普上一任期内,恒生科技指数涨幅超过147%,表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ENTG","EVRG","ODFL","GTLB","LPLA","BPOP","QID","PCAR","SWKS","USJW.SI","AUR","TLN","RYAAY","ALNY","ANSS","HST","FTAI","CDW","RGLD","TTD","LU1815336091.USD","LECO","HOLX","MNST","AFRM","ADBE","RKLB","MPWR","MIDD","REGN","NBIX","FFIV","HSIC","META","AMZN","AMAT","INTU","ONC","AXON","MCHP","LI","AMGN","MEDP","SRPT","RVMD","ORLY","BK4561","OTEX","INSM","MARA","PARA","SBUX","TQQQ","TW","CASY","NVMI","CSWI","TER","MNDY","SEIC","USAW.SI","FCNCA","LU2065731478.USD","BK4550","MKTX","CWST","EWBC","MRNA","OLED","CFLT","NTAP","ULTA","HQY","PFG","EQIX","PTC","CHTR","ROIV","ERIC","NICE","PSQ","ENPH","BRKR","NTES","IDXX","TXN","ZS","MANH","SNPS","BKR","GEN","SMCI","ZM","WTFC","PLTR","MTSI","GEHC","CPRT","PCVX","BMRN","DASH","HOOD","GMAB","JBHT","SSNC","NDAQ","HTHT","SFM","ON","NTNX","BIIB","TSEM","ITCI","ADSK","TEAM","AAL","APA","LNT","EXPE","FTNT","FYBR","CRWD","CTSH","CCEP","BK4588","SBAC","SIRI","NDSN","QXO","STLD","CME","DPZ","FWONK","LAMR","BPMC","JKHY","SOFI","CHDN","TECH","NTRA","DSGX","LSCC","BSY","GILD","MSFT","AAPL","CHRD","NVDA","LOGI","CG","ALGN","COIN","QCOM","FOXA","LU0053671581.USD","GOOGL","MTCH","RADX","CSX","BK4585","DKNG","CSCO","LSTR","WDC","AGNC","NXPI","OKTA","TTEK","CYBR","ROST","BK4593","NWSA","DOCU","PODD","CBSH","INTC","LU0757428866.USD","CSGP","INCY","GNTX","AEP","COO","FAST","FSV","PCTY","ISRG","KDP","PNFP","ROKU","AKAM","FRPT","QQQ","REG","NQmain","LIN","TSCO","DDOG","AMD","COST","BK4534","CHRW","MDLZ","FSLR","QLD","Z","ASML","CDNS","MELI","SQQQ",".IXIC","CINF","EBAY","JD","RIVN","SAIA","ILMN","GRAB","MKSI","TROW","LNW","MRVL","NFLX","LULU","WYNN","DLTR","QRVO","BKNG","TMUS","WWD","ICLR","ARGX","CEG","TCOM","HBAN","TSLA","EXAS","TRMB","EXE","TPG","PEP","ALAB","BK4086","BK4581","ARM","LKQ","DOX","AZN","KHC","ESLT","HLNE","RPRX","DUOL","COKE","MNQmain","FER","PAA","FOX","GLPI","MDB","AVGO","PAYX","TTWO","ROP","MMYT","NVIW.SI","EA","AAON","ADI","HON","CPB","CHKP","POOL","CTAS","ERIE","PDD","STX","WBA","NTRS","TSYW.SI","CZR","RGEN"],"gpt_icon":1},{"id":"2485145218","title":"Roivant Sciences Ltd.盘中异动 下午盘快速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485145218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485145218?lang=zh_cn&edition=full","pubTime":"2024-11-23 02:35","pubTimestamp":1732300530,"startTime":"0","endTime":"0","summary":"北京时间2024年11月23日02时35分,Roivant Sciences Ltd.股票出现异动,股价急速上涨5.03%。截至发稿,该股报12.42美元/股,成交量625.79万股,换手率0.86%,振幅5.37%。Roivant Sciences Ltd.股票所在的生物技术行业中,整体涨幅为0.82%。Roivant Sciences Ltd.公司简介:Roivant Sciences Ltd是一家处于商业阶段的生物制药公司,致力于改善向患者提供医疗保健。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123023530a24e829e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123023530a24e829e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0523},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.3401},{"period":"6month","weight":1.0219},{"period":"1year","weight":1.124},{"period":"ytd","weight":0.0659}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Roivant Sciences Ltd.是一家于2020年7月6日成立的注册于百慕大群岛的公司。Roivant的使命是通过将每一个低效率都视为机会来改善为患者提供的医疗保健服务。Roivant通过以创造性的方式构建技术和培养人才,利用Roivant平台推出“Vants”——灵活且专注的生物制药和健康技术公司,从而更快地开发变革性药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.059962},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004587},{"month":3,"riseRate":0,"avgChangeRate":-0.096551},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Roivant Sciences Ltd.(ROIV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}